HEART Score Calculator for Chest Pain Risk

Chest pain accounts for a large share of emergency department attendances, yet only a minority represents acute coronary syndrome. The HEART score exists to sort that population by six-week risk of major adverse cardiac events, meaning all-cause death, myocardial infarction or coronary revascularisation. Five elements each score 0, 1 or 2: History, ECG, Age, Risk factors and Troponin. The design intent was to formalise what experienced clinicians already weigh rather than to derive weights statistically, which is why it mixes a frankly subjective element (how anginal the story sounds) with objective evidence of ischemia (ST deviation, troponin release) and pretest probability (age, atherosclerotic risk factors). A total of 0 to 3 is low risk with a MACE rate near 1.7 percent, 4 to 6 moderate at roughly 12 to 17 percent, and 7 to 10 high at 50 to 65 percent. Several caveats bear on interpretation. The History element carries poor inter-rater agreement and is the weakest link in reproducibility. The score requires a troponin result, so it cannot triage at first contact, and the 1 to 3 times upper limit bands were defined for older conventional assays; high-sensitivity troponin shifts what an elevation means and most modern protocols pair the score with serial sampling. It was not developed for patients with STEMI or otherwise obvious acute coronary syndrome, who bypass risk scoring entirely, and it should supplement rather than replace clinical judgement.

The score was created by A. J. Six and Barbra Backus, cardiologists working in the Netherlands, and first described in the Netherlands Heart Journal in 2008 in a paper titled Chest pain in the emergency room: value of the HEART score. Six built it from clinical reasoning and a small cohort in Zwolle rather than by regression on trial data. That approach was a reaction to the tools then available: the TIMI risk score had been derived from the TIMI 11B and ESSENCE trial populations and GRACE from a registry, both consisting of patients already diagnosed with acute coronary syndrome, so neither performed well on the undifferentiated chest pain that actually arrives at an emergency department. A multicentre prospective validation followed, with Backus and colleagues reporting 2,440 patients across ten Dutch hospitals in the International Journal of Cardiology in 2013, confirming that low scores identified a group with very low event rates. The decisive step came in 2015, when Simon Mahler and coworkers at Wake Forest published the HEART Pathway randomised trial in Circulation: Cardiovascular Quality and Outcomes. Combining the score with serial troponin measurement, the pathway cut objective cardiac testing and shortened length of stay without missing adverse events at thirty days. That trial moved the score from a European bedside heuristic into formal accelerated diagnostic protocols across North American and European emergency departments.